Priority Partners MCO
7231 Parkway Drive, Suite 100
Hanover, MD 21076

JOHNS HOPKINS
MEDICINE
JOHNS HOPKINS
HEALTHCARE

Prior Authorization

JOHNS HOPKINS HEALTHCARE (MEDICAID)

Otezla - Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to Johns Hopkins Healthcare at **1-410-424-4607**.
Please contact Johns Hopkins Healthcare at **1-888-819-1043** with questions regarding the Prior Authorization process.
When conditions are met, we will authorize the coverage of Otezla - Priority Partners MCO.

Drug Name (select from list of drugs shown)
Otezla (apremilast)

Quantity　　Frequency　　Strength
Route of Administration　　Expected Length of Therapy

Patient Information
Patient Name: ______________________
Patient ID: ______________________
Patient Group No.: ______________________
Patient DOB: ______________________
Patient Phone:

Prescribing Physician
Physician Name: ______________________
Physician Phone: ______________________
Physician Fax: ______________________
Physician Address: ______________________
City, State, Zip: ______________________

Diagnosis: ______________________ **ICD Code:** ______________________

Comments: ______________________

Please circle the appropriate answer for each question.

1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)? Y N

NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.

[If yes, skip to question 13.]

Question	Response	
2. Does the patient have a diagnosis of active psoriatic arthritis?	Y N	
NOTE: Submission of medical records is required.		
[If no, skip to question 4.]		
3. Has the patient tried and had insufficient response to at least two disease-modifying antirheumatic drugs (DMARDs), including methotrexate, unless contraindicated?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 7.]		
[If no, no further questions.]		
4. Does the patient have a diagnosis of moderate to severe plaque psoriasis?	Y N	
NOTE: Submission of medical records is required.		
[If no, skip to question 8.]		
5. Does the patient experience one of the following: A) body surface area involvement of greater than 5%, or B) body surface area involvement less than or equal to 5%, but involves sensitive areas (palms/soles of feet, genitalia, head, or neck)?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
6. Has the patient tried and had insufficient response to phototherapy, or systemic disease-modifying antirheumatic drug (DMARD) therapy with methotrexate, unless contraindicated?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
7. Has the patient tried and had insufficient response to Enbrel, Humira, or Cosentyx?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 11.]		
[If no, no further questions.]		
8. Does the patient have diagnosis of Behcet's disease associated oral ulcers?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
9. Does the patient have at least two oral ulcers?	Y N	
[If no, no further questions.]		
10. Has the patient tried and had insufficient response to at least one non-biologic agent (oral or topical corticosteroids, colchicine)?	Y N	
NOTE: Submission of medical records is required.		

[If no, no further questions.]	
11. Will the requested drug be used concurrently with a biologic disease-modifying antirheumatic drug (DMARD)?	Y N
[If yes, no further questions.]	
12. Is the patient 18 years of age or older?	Y N
[No further questions.]	
13. Is the patient experiencing continual benefit from treatment?	Y N
NOTE: Submission of medical records is required.	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date